FDA Staff Raise Concerns Over Evidence for Popular Compounded Peptides

FDA staff reviewers have expressed doubts regarding the scientific evidence supporting the use of seven widely used peptides, such as BPC-157 and KPV, in compounded medications. This preliminary assessment precedes a late July review by the Pharmacy Compounding Advisory Committee. The committee will decide if these substances should be permitted for compounding, despite public endorsements from some officials. This could impact the availability and use of these products.